Detection and treatment of minimal residual disease in high-risk neuroblastoma.
about
High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastomaHigh-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastomaHigh-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastomaN-(4-hydroxyphenyl)retinamide-induced apoptosis triggered by reactive oxygen species is mediated by activation of MAPKs in head and neck squamous carcinoma cellsLung-residing metastatic and dormant neuroblastoma cells.Preparation and in vitro evaluation of hydrophilic fenretinide nanoparticles.Mesenchymal stromal cell secretome up-regulates 47 kDa CXCR4 expression, and induce invasiveness in neuroblastoma cell lines.Antagonism of cytotoxic chemotherapy in neuroblastoma cell lines by 13-cis-retinoic acid is mediated by the antiapoptotic Bcl-2 family proteinsIn vitro activities of novel 4-HPR derivatives on a panel of rhabdoid and other tumor cell lines.Immunotherapy of neuroblastoma: present, past and future.Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma.Novel Platinum(II) compounds modulate insulin-degrading enzyme activity and induce cell death in neuroblastoma cells.Expression of Wilms tumor gene in high risk neuroblastoma: complementary marker to tyrosine hydroxylase for detection of minimal residual disease.Minimal disease detection in peripheral blood and bone marrow from patients with non-metastatic neuroblastoma.Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models.
P2860
Q24186636-C5D7096A-8388-4199-81FD-698BD46A0967Q24200296-E3709883-0F6A-44DF-AA22-EDA0D4032026Q24235309-890641F6-D23A-43EC-94F1-587684B20D46Q34594976-AB2F7AEA-5A17-41CC-AEBD-7019626017CBQ35070130-85E5FE82-BB09-4B6F-9ECC-16357829C0E3Q35137881-880D1766-3C73-477A-B4BC-FE7A48928331Q35181510-59B5E2D3-0852-4B04-9E2B-ED459E6162E8Q35238042-5711A1F1-15F1-428F-97BB-B3FDFA9A0EE7Q35477972-9D91560E-82AE-41E6-B322-18D70C09E535Q36453273-6B107D34-BF76-4E02-BE57-C880F3E0D4C1Q38876333-D13DCE7D-6AE0-4EA0-BA65-AB0030761A1EQ38934781-E96FA313-7B25-4310-AC56-91F51F48B0FEQ43066010-1B4EBF14-F816-46B7-90A1-E95D6986540DQ54362742-CA14C447-6BE8-4A7E-8762-48F46D6B63E8Q55555244-DB337442-F1C6-4F59-BB3E-1D8CD1587B17
P2860
Detection and treatment of minimal residual disease in high-risk neuroblastoma.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Detection and treatment of minimal residual disease in high-risk neuroblastoma.
@ast
Detection and treatment of minimal residual disease in high-risk neuroblastoma.
@en
type
label
Detection and treatment of minimal residual disease in high-risk neuroblastoma.
@ast
Detection and treatment of minimal residual disease in high-risk neuroblastoma.
@en
prefLabel
Detection and treatment of minimal residual disease in high-risk neuroblastoma.
@ast
Detection and treatment of minimal residual disease in high-risk neuroblastoma.
@en
P1476
Detection and treatment of minimal residual disease in high-risk neuroblastoma
@en
P2093
C Patrick Reynolds
P2860
P356
10.1111/J.1398-2265.2004.00216.X
P478
P50
P577
2004-06-01T00:00:00Z